Repeat renal biopsy in lupus nephritis – unnecessary harm and risk of complications or important diagnostic toll with clinical consequences?
Data nadesłania: 11-04-2016
Data akceptacji: 13-04-2016
Data publikacji online: 03-06-2016
Data publikacji: 30-04-2016
Reumatologia 2016;54(2):49-50
Renal biopsy at the diagnosis of lupus nephritis is well known standard of care, but the same procedure in the subsequent management is still a matter of debate. This editorial summarize the current value of repeat renal biopsy in lupus nephritis. According to the current standard of care in lupus nephritis the induction treatment is followed by maintenance therapy with mycophenolate mofetil (MMF) or azathioprine (AZA) for at least 3 years is indicated. At the end of therapy, because clinical symptoms can be absent and laboratory tests can be normal in patients with active disease. This article brings some arguments in favour of renal biopsy in lupus nephritis.
Austin HA 3rd, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
Lee HS, Mujais SK, Kasinath BS, et al. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984; 77: 612-620.
Daleboudt GM, Bajema IM, Goemaere NN, et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24: gfp359.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top